Results 11 to 20 of about 2,440 (155)

Typhoid Conjugate Vaccine: A Boon for Endemic Regions. [PDF]

Cureus
Typhoid fever has the highest disease burden in countries in low- and middle-income countries, primarily located in Asia and Sub-Saharan Africa. Previous typhoid vaccines such as the live attenuated typhoid (Ty21a) vaccine and Vi (virulence) capsular polysaccharide vaccine had the limitation that they could not be administered with other standard ...
Agarwal N, Gupta N, Nishant, H S S, Dutta T, Mahajan M.   +5 more
europepmc   +3 more sources

An observer-blinded, cluster randomised trial of a typhoid conjugate vaccine in an urban South Indian cohort [PDF]

Trials, 2023
Background Typhoid fever causes nearly 110,000 deaths among 9.24 million cases globally and disproportionately affects developing countries. As a control measure in such regions, typhoid conjugate vaccines (TCVs) are recommended by the World Health ...
Nikhil Sahai, Dilesh Kumar Arunachalam, Tim Morris, Andrew Copas, Prasanna Samuel, Venkata Raghava Mohan, Vinod Abraham, Joshua Anish Selwyn, Praveen Kumar, Winsley Rose, Veeraraghavan Balaji, Gagandeep Kang, Jacob John   +12 more
doaj   +2 more sources

Typhoid Conjugate Vaccine: An Urgent Tool to Combat Typhoid and Tackle Antimicrobial Resistance. [PDF]

J Infect Dis, 2021
Abstract Typhoid is endemic in many countries in South Asia and sub-Saharan Africa. The high burden of this age-old, preventable disease exacerbates constraints on the health systems of these countries. Currently, most patients are treated effectively in the community or outpatient departments, but with rising antimicrobial resistance ...
Saha SK, Tabassum N, Saha S.
europepmc   +4 more sources

Development of Vi conjugate – a new generation of typhoid vaccine [PDF]

Expert Review of Vaccines, 2013
Typhoid fever remains to be a serious disease burden worldwide with an estimated annual incidence about 20 million. The licensed vaccines showed moderate protections and have multiple deficiencies. Most important of all, none of the licensed typhoid vaccines demonstrated protection for children under 5 years old.
exaly   +4 more sources

From Misinformation to Public Distrust: Urgency of Evidence‐Based Transparency, Communication and Community Engagement for Bangladesh's Typhoid Vaccination

Health Science Reports
Background and Aims In Bangladesh, typhoid fever poses a significant threat to public health and has been a major epidemic for many years, especially affecting children from low‐ and middle‐income families due to poor water, sanitation, and seasonal ...
Md. Salauddin, Antu Biswas
doaj   +2 more sources

Strategies to Improve Coverage of Typhoid Conjugate Vaccine (TCV) Immunization Campaign in Karachi, Pakistan

Vaccines, 2020
The emergence and spread of extensively drug-resistant (XDR) typhoid in Karachi, Pakistan led to an outbreak response in Lyari Town, Karachi utilizing a mass immunization campaign with typhoid conjugate vaccine (TCV), Typbar TCV®.
Farah Naz Qamar, Rabab Batool, Sonia Qureshi, Miqdad Ali, Tahira Sadaf, Junaid Mehmood, Khalid Iqbal, Akram Sultan, Noah Duff, Mohammad Tahir Yousafzai   +9 more
doaj   +3 more sources

A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions

Human Vaccines & Immunotherapeutics, 2017
A Typhoid Conjugate Vaccine (TCV) is expected to acquire WHO prequalification soon, which will pave the way for its use in many low- and middle-income countries where typhoid fever is endemic.
Vittal Mogasale, Enusa Ramani, Il Yeon Park, Jung Seok Lee   +3 more
doaj   +2 more sources

Effective strategies for typhoid conjugate vaccine delivery: Health and economic insights from the 2015 Kampala outbreak. [PDF]

PLoS Neglected Tropical Diseases
Typhoid fever remains a major public health threat in low- and middle-income countries (LMICs), where inadequate access to clean water and sanitation drives recurrent outbreaks.
Yeonsu Lee, Pamela Kim N Salonga, Changdae Son, Geunsoo Jang, Dae-Hyup Koh, Jong-Hoon Kim, Hyojung Lee   +6 more
doaj   +2 more sources

A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity [PDF]

Tropical Diseases, Travel Medicine and Vaccines
Background Typhoid fever is commonly found until today, especially in developing countries. It has fatal complications and measures must be taken to reduce the incidence of typhoid. Vaccinations are a key factor in prevention.
Sukamto Koesnoe, Bernie Endyarni Medise, Iris Rengganis, Sri Rezeki Hadinegoro, Mita Puspita, Rini Mulia Sari, Jae Seung Yang, Sushant Sahastrabuddhe, Soedjatmiko, Hartono Gunardi, Rini Sekartini, Angga Wirahmadi, Aria Kekalih, Sreshta Mukhi, Hindra Irawan Satari, Novilia Sjafri Bachtiar   +15 more
doaj   +2 more sources

Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial

International Journal of Infectious Diseases, 2021
Objectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority.
Sodiomon B. Sirima, Alphonse Ouedraogo, Nouhoun Barry, Mohamadou Siribie, Alfred Tiono, Issa Nébié, Amadou Konaté, Gloria Damoaliga Berges, Amidou Diarra, Moussa Ouedraogo, Edith C. Bougouma, Issiaka Soulama, Alimatou Hema, Shrimati Datta, Yuanyuan Liang, Elizabeth T. Rotrosen, J. Kathleen Tracy, Leslie P. Jamka, Jennifer J. Oshinsky, Marcela F. Pasetti, Kathleen M. Neuzil, Matthew B. Laurens   +21 more
doaj   +3 more sources